Regulation and biological activities of the autotaxin-LPA axis

Progress in Lipid Research

Volumn 46, Issue 2, 2007, Pages 145-160

  van Meeteren, Laurens A ^a   Moolenaar, Wouter H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Autotaxin; G Protein coupled receptor; Lysophosphatidic acid; Nucleotide pyrophosphatase phosphodiesterase; Phospholipase D

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPASE; LYSOPHOSPHOLIPASE D; NUCLEOTIDE PYROPHOSPHATASE; PHOSPHOLIPASE; SPLEEN EXONUCLEASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; CANCER; CARBOXY TERMINAL SEQUENCE; ENDOTHELIUM CELL; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM; WOUND HEALING;

ANIMALS; HUMANS; LYSOPHOSPHOLIPIDS; MULTIENZYME COMPLEXES; PHOSPHODIESTERASE I; PYROPHOSPHATASES; RECEPTORS, LYSOPHOSPHATIDIC ACID; SUBSTRATE SPECIFICITY;

EID: 34247534260     PISSN: 01637827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plipres.2007.02.001     Document Type: Review

References (104)

1. van Corven E.J., Groenink A., Jalink K., Eichholtz T., and Moolenaar W.H. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell 59 (1989) 45-54
2. van der Bend R.L., Brunner J., Jalink K., van Corven E.J., Moolenaar W.H., and van Blitterswijk W.J. Identification of a putative membrane receptor for the bioactive phospholipid, lysophosphatidic acid. EMBO J 11 (1992) 2495-2501
3. Eichholtz T., Jalink K., Fahrenfort I., and Moolenaar W.H. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 291 (1993) 677-680
4. Moolenaar W.H. Development of our current understanding of bioactive lysophospholipids. Ann N Y Acad Sci 905 (2000) 1-10
5. Tokumura A., Majima E., Kariya Y., Tominaga K., Kogure K., Yasuda K., et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 277 (2002) 39436-39442
6. Umezu-Goto M., Kishi Y., Taira A., Hama K., Dohmae N., Takio K., et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158 (2002) 227-233
7. Stracke M.L., Krutzsch H.C., Unsworth E.J., Arestad A., Cioce V., Schiffmann E., et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 267 (1992) 2524-2529
8. Moolenaar W.H., van Meeteren L.A., and Giepmans B.N. The ins and outs of lysophosphatidic acid signaling. Bioessays 26 (2004) 870-881
9. Anliker B., and Chun J. Lysophospholipid G protein-coupled receptors. J Biol Chem 279 (2004) 20555-20558
10. Sano T., Baker D., Virag T., Wada A., Yatomi Y., Kobayashi T., et al. Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem 277 (2002) 21197-21206
11. Balazs L., Okolicany J., Ferrebee M., Tolley B., and Tigyi G. Topical application of the phospholipid growth factor lysophosphatidic acid promotes wound healing in vivo. Am J Physiol Regul Integr Comp Physiol 280 (2001) R466-R472
12. Sturm A., and Dignass A.U. Modulation of gastrointestinal wound repair and inflammation by phospholipids. Biochim Biophys Acta 1582 (2002) 282-288
13. Sugiura T., Nakane S., Kishimoto S., Waku K., Yoshioka Y., and Tokumura A. Lysophosphatidic acid, a growth factor-like lipid, in the saliva. J Lipid Res 43 (2002) 2049-2055
14. Sauer B., Vogler R., Zimmermann K., Fujii M., Anzano M.B., Schafer-Korting M., et al. Lysophosphatidic acid interacts with transforming growth factor-beta signaling to mediate keratinocyte growth arrest and chemotaxis. J Invest Dermatol 123 (2004) 840-849
15. Ashcroft G.S., Yang X., Glick A.B., Weinstein M., Letterio J.L., Mizel D.E., et al. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1 (1999) 260-266
16. Mills G.B., and Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3 (2003) 582-591
17. Boucharaba A., Serre C.M., Gres S., Saulnier-Blache J.S., Bordet J.C., Guglielmi J., et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 114 (2004) 1714-1725
18. Boucharaba A., Serre C.M., Guglielmi J., Bordet J.C., Clezardin P., and Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci USA 103 (2006) 9643-9648
19. Yang M., Zhong W.W., Srivastava N., Slavin A., Yang J., Hoey T., et al. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the β-catenin pathway. Proc Natl Acad Sci USA 102 (2005) 6027-6032
20. Jonkers J., and Berns A. Conditional mouse models of sporadic cancer. Nat Rev Cancer 2 (2002) 251-265
21. Haseruck N., Erl W., Pandey D., Tigyi G., Ohlmann P., Ravanat C., et al. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors. Blood 103 (2004) 2585-2592
22. Siess W., and Tigyi G. Thrombogenic and atherogenic activities of lysophosphatidic acid. J Cell Biochem 92 (2004) 1086-1094
23. Yoshida K., Nishida W., Hayashi K., Ohkawa Y., Ogawa A., Aoki J., et al. Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation 108 (2003) 1746-1752
24. Zhang C., Baker D.L., Yasuda S., Makarova N., Balazs L., Johnson L.R., et al. Lysophosphatidic acid induces neointima formation through PPARγ activation. J Exp Med 199 (2004) 763-774
25. Hayashi K., Takahashi M., Nishida W., Yoshida K., Ohkawa Y., Kitabatake A., et al. Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ Res 89 (2001) 251-258
26. Rother E., Brandl R., Baker D.L., Goyal P., Gebhard H., Tigyi G., et al. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 108 (2003) 741-747
27. Ferry G., Tellier E., Try A., Gres S., Naime I., Simon M.F., et al. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem 278 (2003) 18162-18169
28. Pages G., Girard A., Jeanneton O., Barbe P., Wolf C., Lafontan M., et al. LPA as a paracrine mediator of adipocyte growth and function. Ann N Y Acad Sci 905 (2000) 159-164
29. Simon M.F., Daviaud D., Pradere J.P., Gres S., Guigne C., Wabitsch M., et al. Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor γ2. J Biol Chem 280 (2005) 14656-14662
30. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
31. Schulze C., Smales C., Rubin L.L., and Staddon J.M. Lysophosphatidic acid increases tight junction permeability in cultured brain endothelial cells. J Neurochem 68 (1997) 991-1000
32. Nieuw Amerongen G.P., Vermeer M.A., and van Hinsbergh V.W. Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler Thromb Vasc Biol 20 (2000) E127-E133
33. Neidlinger N.A., Larkin S.K., Bhagat A., Victorino G.P., and Kuypers F.A. Hydrolysis of phosphatidylserine-exposing red blood cells by secretory phospholipase A2 generates lysophosphatidic acid and results in vascular dysfunction. J Biol Chem 281 (2006) 775-781
34. Alexander J.S., Patton W.F., Christman B.W., Cuiper L.L., and Haselton F.R. Platelet-derived lysophosphatidic acid decreases endothelial permeability in vitro. Am J Physiol 274 (1998) H115-H122
35. English D., Kovala A.T., Welch Z., Harvey K.A., Siddiqui R.A., Brindley D.N., et al. Induction of endothelial cell chemotaxis by sphingosine 1-phosphate and stabilization of endothelial monolayer barrier function by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis. J Hematother Stem Cell Res 8 (1999) 627-634
36. Yin F., and Watsky M.A. LPA and S1P increase corneal epithelial and endothelial cell transcellular resistance. Invest Ophthalmol Vis Sci 46 (2005) 1927-1933
37. Jalink K., Eichholtz T., Postma F.R., van Corven E.J., and Moolenaar W.H. Lysophosphatidic acid induces neuronal shape changes via a novel, receptor-mediated signaling pathway: similarity to thrombin action. Cell Growth Differ 4 (1993) 247-255
38. Tigyi G., and Miledi R. Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in PC12 pheochromocytoma cells. J Biol Chem 267 (1992) 21360-21367
39. Fukushima N., Weiner J.A., and Chun J. Lysophosphatidic acid (LPA) is a novel extracellular regulator of cortical neuroblast morphology. Dev Biol 228 (2000) 6-18
40. Yuan X.B., Jin M., Xu X., Song Y.Q., Wu C.P., Poo M.M., et al. Signalling and crosstalk of Rho GTPases in mediating axon guidance. Nat Cell Biol 5 (2003) 38-45
41. Kingsbury M.A., Rehen S.K., Contos J.J., Higgins C.M., and Chun J. Non-proliferative effects of lysophosphatidic acid enhance cortical growth and folding. Nat Neurosci 6 (2003) 1292-1299
42. Fukushima N., Shano S., Moriyama R., and Chun J. Lysophosphatidic acid stimulates neuronal differentiation of cortical neuroblasts through the LPA(1)-G(i/o) pathway. Neurochem Int 50 (2007) 302-307
43. Ramakers G.J., and Moolenaar W.H. Regulation of astrocyte morphology by RhoA and lysophosphatidic acid. Exp Cell Res 245 (1998) 252-262
44. Inoue M., Rashid M.H., Fujita R., Contos J.J., Chun J., and Ueda H. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 10 (2004) 712-718
45. Fujita R., Kiguchi N., and Ueda H. LPA-mediated demyelination in ex vivo culture of dorsal root. Neurochem Int 50 (2007) 351-355
46. Weiner J.A., Fukushima N., Contos J.J., Scherer S.S., and Chun J. Regulation of Schwann cell morphology and adhesion by receptor-mediated lysophosphatidic acid signaling. J Neurosci 21 (2001) 7069-7078
47. Chun J., Goetzl E.J., Hla T., Igarashi Y., Lynch K.R., Moolenaar W., et al. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev 54 (2002) 265-269
48. Lee C.W., Rivera R., Dubin A.E., and Chun J. LPA4/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing Gs-, Gq/Gi-mediated calcium signaling and G12/13-mediated Rho activation. J Biol Chem 282 (2007) 4310-4317
49. Noguchi K., Ishii S., and Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family 1. J Biol Chem 278 (2003) 25600-25606
50. Yanagida K., Ishii S., Hamano F., Noguchi K., and Shimizu T. LPA4/p2y9/GPR23 mediates Rho-dependent morphological changes in a rat neuronal cell line. J Biol Chem 282 (2006) 5814-5824
51. Kotarsky K., Boketoft A., Bristulf J., Nilsson N.E., Norberg A., Hansson S., et al. Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes. J Pharmacol Exp Ther 318 (2006) 619-628
52. Lee C.W., Rivera R., Gardell S., Dubin A.E., and Chun J. GPR92 as a new G12/13 and Gq coupled lysophosphatidic acid receptor that increases cAMP: LPA5. J Biol Chem 282 (2006) 4310-4317
53. Contos J.J., Fukushima N., Weiner J.A., Kaushal D., and Chun J. Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci USA 97 (2000) 13384-13389
54. Contos J.J., Ishii I., Fukushima N., Kingsbury M.A., Ye X., Kawamura S., et al. Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol Cell Biol 22 (2002) 6921-6929
55. Ye X., Hama K., Contos J.J., Anliker B., Inoue A., Skinner M.K., et al. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 435 (2005) 104-108
56. Hama K., Bandoh K., Kakehi Y., Aoki J., and Arai H. Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors 4. FEBS Lett 523 (2002) 187-192
57. Aoki J., Nagai Y., Hosono H., Inoue K., and Arai H. Structure and function of phosphatidylserine-specific phospholipase A1. Biochim Biophys Acta 1582 (2002) 26-32
58. Sciorra V.A., and Morris A.J. Roles for lipid phosphate phosphatases in regulation of cellular signaling. Biochim Biophys Acta 1582 (2002) 45-51
59. Tanaka M., Kishi Y., Takanezawa Y., Kakehi Y., Aoki J., and Arai H. Prostatic acid phosphatase degrades lysophosphatidic acid in seminal plasma. FEBS Lett 571 (2004) 197-204
60. Yue J., Yokoyama K., Balazs L., Baker D.L., Smalley D., Pilquil C., et al. Mice with transgenic overexpression of lipid phosphate phosphatase-1 display multiple organotypic deficits without alteration in circulating lysophosphatidate level 1. Cell Signal 16 (2004) 385-399
61. Tokumura A. Physiological and pathophysiological roles of lysophosphatidic acids produced by secretory lysophospholipase D in body fluids. Biochim Biophys Acta 1582 (2002) 18-25
62. Goding J.W., Grobben B., and Slegers H. Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family. Biochim Biophys Acta 1638 (2003) 1-19
63. Stefan C., Jansen S., and Bollen M. NPP-type ectophosphodiesterases: unity in diversity. Trends Biochem Sci 30 (2005) 542-550
64. Deng G., Royle G., Wang S., Crain K., and Loskutoff D.J. Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem 271 (1996) 12716-12723
65. Gijsbers R., Ceulemans H., Stalmans W., and Bollen M. Structural and catalytic similarities between nucleotide pyrophosphatases/phosphodiesterases and alkaline phosphatases. J Biol Chem 276 (2001) 1361-1368
66. Cimpean A., Stefan C., Gijsbers R., Stalmans W., and Bollen M. Substrate-specifying determinants of the nucleotide pyrophosphatases/phosphodiesterases NPP1 and NPP2. Biochem J 381 (2004) 71-77
67. Jansen S., Stefan C., Creemers J.W., Waelkens E., Van Eynde A., Stalmans W., et al. Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D. J Cell Sci 118 (2005) 3081-3089
68. Koike S., Keino-Masu K., Ohto T., and Masu M. The N-terminal hydrophobic sequence of autotaxin (ENPP2) functions as a signal peptide. Genes Cells 11 (2006) 133-142
69. van Meeteren L.A., Ruurs P., Christodoulou E., Goding J.W., Takakusa H., Kikuchi K., et al. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem 280 (2005) 21155-21161
70. Jansen S., Callewaert N., Dewerte I., Andries M., Ceulemans H., and Bollen M. An essential oligomannosidic glycan chain in the catalytic domain of autotaxin, a secreted lysophospholipase-D. J Biol Chem 282 (2007) 11084-11091
71. Lee H.Y., Murata J., Clair T., Polymeropoulos M.H., Torres R., Manrow R.E., et al. Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells. Biochem Biophys Res Commun 218 (1996) 714-719
72. Murata J., Lee H.Y., Clair T., Krutzsch H.C., Arestad A.A., Sobel M.E., et al. cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases. J Biol Chem 269 (1994) 30479-30484
73. Fuss B., Baba H., Phan T., Tuohy V.K., and Macklin W.B. Phosphodiesterase I, a novel adhesion molecule and/or cytokine involved in oligodendrocyte function. J Neurosci 17 (1997) 9095-9103
74. Kawagoe H., Stracke M.L., Nakamura H., and Sano K. Expression and transcriptional regulation of the PD-Ialpha/autotaxin gene in neuroblastoma. Cancer Res 57 (1997) 2516-2521
75. Bachner D., Ahrens M., Betat N., Schroder D., and Gross G. Developmental expression analysis of murine autotaxin (ATX). Mech Dev 84 (1999) 121-125
76. Hoelzinger D.B., Mariani L., Weis J., Woyke T., Berens T.J., McDonough W.S., et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 7 (2005) 7-16
77. Savaskan N.E., Rocha L., Kotter M.R., Baer A., Lubec G., van Meeteren L.A., et al. Autotaxin (NPP-2) in the brain: cell type-specific expression and regulation during development and after neurotrauma. Cell Mol Life Sci 64 (2007) 230-243
78. Kehlen A., Lauterbach R., Santos A.N., Thiele K., Kabisch U., Weber E., et al. IL-1 beta- and IL-4-induced down-regulation of autotaxin mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis (RA). Clin Exp Immunol 123 (2001) 147-154
79. Umemura K., Yamashita N., Yu X., Arima K., Asada T., Makifuchi T., et al. Autotaxin expression is enhanced in frontal cortex of Alzheimer-type dementia patients. Neurosci Lett 400 (2006) 97-100
80. Hammack B.N., Fung K.Y., Hunsucker S.W., Duncan M.W., Burgoon M.P., Owens G.P., et al. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler 10 (2004) 245-260
81. Williams T.M., Williams M.E., Kuick R., Misek D., McDonagh K., Hanash S., et al. Candidate downstream regulated genes of HOX group 13 transcription factors with and without monomeric DNA binding capability. Dev Biol 279 (2005) 462-480
82. Chen M., and O'Connor K.L. Integrin α6β4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. Oncogene 24 (2005) 5125-5130
83. Black E.J., Clair T., Delrow J., Neiman P., and Gillespie D.A. Microarray analysis identifies autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun. Oncogene (2003)
84. Kishi Y., Okudaira S., Tanaka M., Hama K., Shida D., Kitayama J., et al. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 281 (2006) 17492-17500
85. Croset M., Brossard N., Polette A., and Lagarde M. Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochem J 345 Pt 1 (2000) 61-67
86. Clair T., Aoki J., Koh E., Bandle R.W., Nam S.W., Ptaszynska M.M., et al. Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res 63 (2003) 5446-5453
87. Liliom K., Sun G., Bunemann M., Virag T., Nusser N., Baker D.L., et al. Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. Biochem J 355 (2001) 189-197
88. van Meeteren L.A., Ruurs P., Stortelers C., Bouwman P., van Rooijen M.A., Pradere J.P., et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 26 (2006) 5015-5022
89. Tanaka M., Okudaira S., Kishi Y., Ohkawa R., Iseki S., Ota M., et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem (2006)
90. Mizugishi K., Yamashita T., Olivera A., Miller G.F., Spiegel S., and Proia R.L. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 25 (2005) 11113-11121
91. Vollmayer P., Clair T., Goding J.W., Sano K., Servos J., and Zimmermann H. Hydrolysis of diadenosine polyphosphates by nucleotide pyrophosphatases/phosphodiesterases. Eur J Biochem 270 (2003) 2971-2978
92. Ferguson C.G., Bigman C.S., Richardson R.D., van Meeteren L.A., Moolenaar W.H., and Prestwich G.D. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. Org Lett 8 (2006) 2023-2026
93. Durgam G.G., Virag T., Walker M.D., Tsukahara R., Yasuda S., Liliom K., et al. Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARγ, and inhibitors of autotaxin. J Med Chem 48 (2005) 4919-4930
94. Baker D.L., Fujiwara Y., Pigg K.R., Tsukahara R., Kobayashi S., Murofushi H., et al. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J Biol Chem (2006)
95. Uchiyama A., Mukai M., Fujiwara Y., Kobayashi S., Kawai N., Murofushi H., et al. Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid. Biochim Biophys Acta 1771 (2007) 103-112
96. Nam S.W., Clair T., Campo C.K., Lee H.Y., Liotta L.A., and Stracke M.L. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 19 (2000) 241-247
97. Song J., Clair T., Noh J.H., Eun J.W., Ryu S.Y., Lee S.N., et al. Autotaxin (lysoPLD/NPP2) protects fibroblasts from apoptosis through its enzymatic product, lysophosphatidic acid, utilizing albumin-bound substrate. Biochem Biophys Res Commun 337 (2005) 967-975
98. Zhao H., Ramos C.F., Brooks J.D., and Peehl D.M. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. J Cell Physiol 210 (2007) 111-121
99. Song J., Jie C., Polk P., Shridhar R., Clair T., Zhang J., et al. The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: down-regulation of the potent mitogenic, motogenic, and angiogenic factor autotaxin. Biochem Biophys Res Commun 340 (2006) 175-182
100. Baumforth K.R., Flavell J.R., Reynolds G.M., Davies G., Pettit T.R., Wei W., et al. Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood 106 (2005) 2138-2146
101. Nam S.W., Clair T., Kim Y.S., McMarlin A., Schiffmann E., Liotta L.A., et al. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor 2. Cancer Res 61 (2001) 6938-6944
102. Rogers M.S., Rohan R.M., Birsner A.E., and D'Amato R.J. Genetic loci that control the angiogenic response to basic fibroblast growth factor. FASEB J 18 (2004) 1050-1059
103. Offermanns S., Mancino V., Revel J.P., and Simon M.I. Vascular system defects and impaired cell chemokinesis as a result of Gα13 deficiency. Science 275 (1997) 533-536
104. Ruppel K.M., Willison D., Kataoka H., Wang A., Zheng Y.W., Cornelissen I., et al. Essential role for Galpha13 in endothelial cells during embryonic development. Proc Natl Acad Sci USA 102 (2005) 8281-8286